

Application number
2345800

Registration number
TMA1397681

Type(s)
Standard Characters

Category
Trademark

CIPO Status
REGISTERED

TM5 status
LIVE/REGISTRATION/Issued
and Active



The trademark application has
been registered with the Office.

Filed
2024-08-26

Registered
2026-03-25

Registration Expiry Date
2036-03-25

Registered Owner
Eli Lilly and Company
Eli Lilly Corporate Center
Indianapolis, IN 46285
UNITED STATES OF
AMERICA

Agent
BORDEN LADNER GERVAIS
LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9

Documents
[View documents](#)

Index headings

RAYKASMI

Goods (Nice class & Statement)

5 (1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone diseases and disorders and musculoskeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, eczema, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, diabetes, dyslipidemia, endocrine diseases and disorders, namely, growth and thyroid disorders, diabetes and obesity, and hormonal diseases, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases, inflammatory muscle diseases and disorders and pharmaceutical preparations for the treatment of inflammation, namely anti-inflammatory preparations, pharmaceutical preparations for the treatment of kidney diseases and disorders, liver diseases and disorders, lupus, mental health disorders, metabolic diseases and disorders, namely, diabetes, gout, arthritis and anemia, obesity, hyperlipidemia, insulin resistance and metabolic syndrome, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, namely, Alzheimer's, Huntington's disease, cerebral palsy, brain injury, spinal cord injury, and seizure disorders, amyotrophic lateral sclerosis (ALS), encephalitis, meningitis, muscular dystrophy, myasthenia gravis, dystonia, epilepsy, seizures, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases.

Action History

Action	Action date	Due date	Comments
Filed	2024-08-26		
Created	2024-08-26		
Formalized	2024-08-26		
Pre-Assessment Letter Sent	2024-09-05		Goods or Services Not Acceptable
Search Recorded	2025-03-12		
Examiner's First Report	2025-03-12	2025-09-12	
Correspondence Created	2025-09-15	2026-03-15	
Approved	2025-10-22		APPROVED BY PROGRAM EX200M1
Approval Notice Sent	2025-10-22		APPROVED BY PROGRAM EX200M1
Advertised	2026-01-07		Vol.73 Issue 3715
Registration Pending	2026-03-25		
Registered	2026-03-25	2036-03-25	